Overview

Effectiveness of Ketamine in Malignant Neuropathic Pain Relief

Status:
Withdrawn

Trial end date:
2016-10-01

Target enrollment:
0

Participant gender:
All

Summary

To see whether the addition of low-dose ketamine to a subcutaneous morphine infusion improves analgesia in patients with neuropathic cancer pain.

Phase:

Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Haukeland University Hospital

Treatments:

Ketamine

Criteria

Inclusion Criteria:

Age 18-70 years. In-patient. Cancer pain judged to have a neuropathic component. Clinically
normal renal and hepatic function. Able to cooperate and understand information. Worst pain
at rest or on movement 5 or more (NRS 0-10). Pain currently treated with continuous
subcutaneous morphine infusion. The daily morphine dose is 48mg or more per 24 hours and a
30% increase in the daily dose has not provided sufficient pain relief.

Not treated with ketamine during the last 48 hours prior to inclusion.

-

Exclusion Criteria:

Reduced renal or hepatic function. Suspicion of morphine toxicity (sedation, hallucination,
myoclonus, increasing pain).

Increased intracranial pressure (suspicion of cerebral metastases) or cerebral metastases.

Unable to cooperate/ understand information. Worst pain at rest or on movement less than 5
on NRS. Current treatment with other opioids than morphine. The patient is undergoing
radiotherapy in the pain area, or has received radiotherapy in the pain area within the
last four weeks.

Changes in the use of analgesics (paracetamol, NSAIDS), adjuvant drugs (antidepressants,
antiepileptic, corticosteroids, muscle relaxants) or their dosages less than 2 days prior
to inclusion or during the study period.

Pregnant and lactating women. Any situation in which an increase in blood pressure would
constitute a hazard. Acute intermittent porphyria. Psychiatric illness, epilepsy,
alcoholism, glaucoma. Hypersensitivity to any of the drugs ingredients. Current treatment
with ketamine.

-